Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02698150
Other study ID # HERMES
Secondary ID
Status Recruiting
Phase N/A
First received February 26, 2016
Last updated September 8, 2017
Start date March 2016
Est. completion date October 2018

Study information

Verified date September 2017
Source Azienda Ospedaliero, Ferrarotto Alessi
Contact Corrado Tamburino, Professor
Email tambucor@unict.it
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

HERMES is a pilot study which aims at exploring the impact of remote monitoring in patients with severe functional mitral regurgitation undergoing transcatheter mitral valve edge-to-edge repair with the Mitraclip system.


Description:

The scope of the HERMES study is to investigate whether the information obtained by remote monitoring in patients with severe functional mitral regurgitation who have undergone transcatheter mitral valve edge-to-edge repair with the Mitraclip system may have the potential to guide treatment decisions at follow-up visits, and improve the quality of life. Candidates to the Mitraclip procedure on optimal medical therapy will be offered the opportunity to participate to the study by bringing home a tablet and a series of sensors and wearables to collect daily information on blood pressure, oxygen saturation, weight variation, heart rate, symptoms and compliance to therapy. These variables will be blinded, stored by the tablet and downloaded by the core institution at follow-up visits. Clinicians will be encouraged to use these data to guide their decisions, personalizing drug therapies and follow-up schedules to the individual patient's need. Patients that during the run-in phase (from enrollment to 30+-7 days) will have used the tablet for >66% of the days will undergo the Mitraclip procedure and continue to keep the tablet for up to 12 months (active group). Patients that during the run-in phase (from enrollment to 30+-7 days) will have not used the tablet for >66% of the days, will continue the study as a control group. Predefined clinical follow up assessments for collection of study endpoints will be at 1 month post Mitraclip, 6 months post Mitraclip and 12 months post Mitraclip. Quality of life, assessed by means of the SF36v2 questionnaire, will be assessed at enrollment, pre Mitraclip, at 1 month after Mitraclip and at 12 months after Mitraclip. A series of secondary endpoints, including 6MWT assessments and consumption of resources will be also assessed.


Recruitment information / eligibility

Status Recruiting
Enrollment 55
Est. completion date October 2018
Est. primary completion date September 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Symptomatic while on optimal medical therapy (NYHA Class III-IV)

- Mitral regurgitation of functional etiology

- Suitable Mitraclip candidate

- Life expectancy >12 months

Exclusion Criteria:

- Mitral regurgitation of primary etiology

- Refusal to sign the informed consent

- Dementia or neurological disorders that prevent the proper use of the tablet

- Inability to use the tablet, the sensors and/or the wearables, even with the assistance of family members

- Expected non-compliance with follow-up visits

- End-stage chronic kidney disease on dialysis

Study Design


Intervention

Device:
HERMES tablet
Tablet, sensors and wearables for daily collection of clinical data

Locations

Country Name City State
Italy Ferrarotto Hospital Catania

Sponsors (2)

Lead Sponsor Collaborator
Azienda Ospedaliero, Ferrarotto Alessi Abbott Vascular

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Other 6MWT (6-minute walking test) Baseline
Other 6MWT (6-minute walking test) 1 month after Mitraclip implant
Other 6MWT (6-minute walking test) 6 months after Mitraclip implant
Other 6MWT (6-minute walking test) 12 months after Mitraclip implant
Primary Quality of life @ 12 months Quality of life assessed with the SF36v2 questionnaire at 12 months post Mitraclip implant 12 months
Secondary Quality of life @ baseline Quality of life assessed with the SF36v2 questionnaire at 1 month before Mitraclip implant Baseline (1 month before Mitraclip implant)
Secondary Quality of life @ index procedure (end of the run-in phase) Quality of life assessed with the SF36v2 questionnaire at the time of the Mitraclip procedure pre Mitraclip implant
Secondary Quality of life @ 1 month Quality of life assessed with the SF36v2 questionnaire at 1 month after Mitraclip implant 1 month after Mitraclip implant
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy